Lexicon Pharmaceuticals Q3 2021 Earnings Report
Key Takeaways
Lexicon Pharmaceuticals reported its third quarter 2021 financial results, with revenues being negligible compared to the previous year due to the sale of XERMELO®. Research and development expenses decreased, as did selling, general, and administrative expenses. The net loss for the quarter was $23.1 million, compared to a net income of $82.6 million in the same period of 2020, which included a gain from the sale of XERMELO®.
On track for submission around year-end of new drug application for sotagliflozin for the treatment of heart failure in patients with type 2 diabetes.
ESC issued new treatment guidelines adding SGLT inhibitors to the standard of care for the prevention and treatment of heart failure.
Patient enrollment continued in two ongoing Phase 2 clinical studies of LX9211 for the treatment of diabetic peripheral neuropathic pain and the treatment of post-herpetic neuralgia.
Craig B. Granowitz, M.D., Ph.D. joined Lexicon as senior vice president and chief medical officer.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Forward Guidance
Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update.